CVS Health (CVS) Tops Q1 EPS by 33c, Raises FY EPS Guidance

CVS Health (NYSE: CVS) reported Q1 EPS of $2.04, $0.33 better than the analyst estimate of $1.71. Revenue for the quarter came in at $69.1 billion versus the consensus estimate of $68.29 billion.

GUIDANCE:

CVS Health sees FY2021 EPS of $7.56-$7.68, versus the consensus of $7.53.

• The Company raised its full year 2021 GAAP diluted EPS guidance range to $6.24 to $6.36 from $6.06 to $6.22 and its full year 2021 Adjusted EPS guidance range to $7.56 to $7.68 from $7.39 to $7.55 and confirmed its full year 2021 cash flow from operations guidance range of $12.0 billion to $12.5 billion.

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance